Related Experiment Video
Updated: Jun 7, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct
Minyoung Park1, Hisae Matsuura, Robert A Lamb
1Department of Chemical and Systems Biology, Stanford University School of Medicine, CA 94305, USA.
Insights
New methods to combat human respiratory syncytial virus (hRSV) are needed. Researchers developed a new assay using an engineered hRSV F protein 5-helix bundle (5HB) to discover potential antiviral peptides that inhibit viral fusion.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Human respiratory syncytial virus (hRSV) causes severe respiratory infections, particularly in young children.
- There are currently no FDA-approved therapeutics to control hRSV infection.
- The hRSV F protein mediates viral fusion, a key target for antiviral intervention.
Purpose of the Study:
- To develop a novel assay for identifying inhibitors of hRSV fusion.
- To validate an engineered 5-helix bundle (5HB) of the hRSV F protein as a screening tool.
- To discover short peptides that can disrupt the hRSV F protein's postfusion 6-helix bundle (6HB) formation.
Main Methods:
- Development and validation of a fluorescence polarization (FP) assay utilizing an engineered hRSV F protein 5-helix bundle (5HB).
- Generation and characterization of the 5HB to confirm its ability to form a 6HB.
- Screening of truncated peptides derived from the hRSV F protein's sixth helix using the FP-based 5HB system.
Main Results:
- The engineered 5HB system successfully validated the formation of a 6HB.
- Short peptides derived from the sixth helix were identified as inhibitors of 6HB formation.
- These peptides demonstrated the potential to block hRSV fusion.
Conclusions:
- The developed FP-based 5HB system is an effective tool for screening potential hRSV antivirals.
- Short peptides targeting the hRSV F protein's 6HB represent promising candidates for therapeutic intervention.
- This approach facilitates the discovery and study of novel antivirals against hRSV infection.
Abstract:
Human respiratory syncytial virus (hRSV) typically affects newborns and young children. Even though it can cause severe and, in some cases, lifelong respiratory infections, there are currently no Food and Drug Administration (FDA)-approved therapeutics that control this virus. The hRSV F protein facilitates viral fusion, a critical extracellular event that can be targeted for therapeutic intervention by disrupting the assembly of a postfusion 6-helix bundle (6HB) within the hRSV F protein. Here we report the development of a fluorescence polarization (FP) assay using an engineered hRSV F protein 5-helix bundle (5HB). We generated the 5HB and validated its ability to form a 6HB in an FP assay. To test the potential of 5HB as a screening tool, we then investigated a series of truncated peptides derived from the "missing" sixth helix. Using this FP-based 5HB system, we have successfully demonstrated that short peptides can prevent 6HB formation and serve as potential hRSV fusion inhibitors. We anticipate that this new 5HB system will provide an effective tool to identify and study potential antivirals to control hRSV infection.
